Showing 15 posts of 273 posts found.


Janssen submits sNDA to FDA for full approval of Balversa

August 29, 2023
Research and Development Balversa, FDA, Janssen, Oncology

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental New Drug Application (sNDA) to …

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …


FDA approves Talvey for the treatment of heavily pretreated multiple myeloma

August 11, 2023
Medical Communications FDA, J&J, Janssen, Oncology, Talvey, multiple myeloma

The Janssen Pharmaceutical companies of Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has granted …

Nanobiotix announces license agreement with Janssen for development and commercialisation of new cancer treatment

July 10, 2023
Sales and Marketing Cancer, Janssen, License Agreement, Oncology, nanobiotix

Nanobiotix has announced a global licensing, co-development and commercialisation agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies …


Janssen CLL treatment combination sees success in trials

June 14, 2021
Sales and Marketing CLL, Janssen

Janssen has announced positive data from its Phase III GLOW study, with the combination of imbruvica (ibrutinib) plus venetoclax (I+V) …

NICE recommends Janssen’s active psoriatic arthritis drug

May 28, 2021
Medical Communications Janssen, NICE, UK, arthritis

NICE have released a Final Appraisal Document (FAD) recommending Janssen’s tremfya (guselkumab) as a new option for treating active psoriatic …


Janssen sees promising PRO data for prostate cancer therapy

May 27, 2021
Janssen, prostate cancer

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …


Janssen submits MAA to EMA for novel CAR-T cell therapy

May 5, 2021
Research and Development EMA, EU, Janssen, multiple myeloma

Janssen have submitted a Marketing Authorisation Application (MAA) to the EMA seeking approval of cilta-cel, an investigational B cell maturation …

J&J vaccine halted in US due to blood clots

April 14, 2021
Research and Development CDC, COVID-19 vaccine, FDA, Janssen, Johnson & Johnson, pharma, pharma news

The CDC and FDA have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine in the …

Janssen sign

Janssen agrees $780 million deal for authorisation of Cidara flu treatment

April 6, 2021
Manufacturing and Production Janssen, cidara, influenza

Janssen has struck a deal worth up to $780 million with Cidara Therapeutics for exclusive worldwide rights to Cidara’s CD388 …

J & J to ship up to 400 million vaccines to Africa

March 30, 2021
Manufacturing and Production COVAX, COVID-19, COVID-19 vaccine, Janssen, Johnson & Johnson

Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to …

Janssen’s multiple sclerosis treatment recommended by EMA

March 29, 2021
Sales and Marketing CHMP, EMA, Janssen, Johnson & Johnson, PONVORY, multiple sclerosis

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) has been recommended by the …

Janssen sign

Johnson & Johnson’s arthritis drug shows promising results in Phase III trial

March 16, 2021
Manufacturing and Production Janssen, Johnson & Johnson, PSA, Tremfya, arthritis

Johnson & Johnson’s TREMFYA treatment for active Psoriatic Arthritis (PsA) has returned positive results in its Phase III trial.

Beyond Batten Disease Foundation partners with Actelion on development of combination treatment

March 4, 2021
Actelion, Batten disease, Janssen

Beyond Batten Disease Foundation (BBDF) has partnered with Actelion Pharmaceuticals, a Janssen company, to provide Zavesca (miglustat) for the development of …

FDA approves Johnson & Johnson’s COVID-19 vaccine for emergency use

March 1, 2021
Sales and Marketing COVID-19, Janssen, Johnson & Johnson, vaccines

The FDA has issued emergency use authorisation for Johnson & Johnson’s one-shot COVID-19 vaccine, approving the jab for use in …

Latest content